MedPath

Assessment Metabolic Flexibility in Middle-aged Individuals: The Nutritional Impact of Cheese Consumption

Not Applicable
Recruiting
Conditions
Nutrition
Metabolism
Interventions
Dietary Supplement: kent'erbas cheese study
Registration Number
NCT06012227
Lead Sponsor
University of Cagliari
Brief Summary

The aim of the study will be to evaluate the impact of consumption of meat and dairy products from extensive or intensive farming on apparently healthy individuals aged between 45 and 65 years, a stage of life associated with reduced metabolic flexibility and changes in lipid metabolism.

The study will analyze:

1. The transcription factor PPAR-α determined by the gene expression of PPAR-α in white blood cells, variations in circulating fatty acid metabolism, and the endocannabinoid system determined by circulating analysis of N-acylethanolamine (NAE), and 2-monoacylglycerols (2-MG);

2. Metabolic flexibility, determined by indirect calorimetry in fasting condition during an incremental exercise;

3. Body composition, determined by bioimpedance analysis, waist circumference, and waist-to-hip ratio.

Detailed Description

The study will be a double-blind crossover intervention clinical trial conducted on the aforementioned individuals, who will consume "kent'erbas" cheese products, from extensive and intensive farming.

The study will include 105 individuals aged between 45 and 65 years, apparently in good health, recruited from the UTIC cardiology unit of A.O.U.CA Cagliari (Italy). All participants will be provided with a detailed explanation of the study procedures and its purpose, and their participation will be contingent upon signing an informed consent form. Throughout the study, subjects will maintain their regular lifestyle and unrestricted food intake.

At the outset of the study, relevant information necessary for an appropriate approach to each participant will be collected, including a comprehensive medical history, measurement of anthropometric parameters, and blood sampling for a thorough hematological, inflammatory, and lipid-metabolomic analysis.

In the pecorino study, subjects will consume 350g/week of "kent'erbas" pecorino from extensive farming or 350g/week of "industrial" pecorino from intensive farming for 4 weeks in total. At the end of this period, a blood sample will be taken. Subsequently, there will be a 8 weeks washout period during which participants will follow their usual diet without consuming either type of pecorino. At the end of the washout period, an additional blood sample will be taken. Following this, the participants who had consumed "kent'erbas" pecorino will switch to "industrial" pecorino for 4 weeks, and vice versa. At the end of this second period, a final blood sample will be collected.

The quantities of pecorino cheese chosen for intake are representative of the average consumption in Italy.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
105
Inclusion Criteria
  • 45-65 years of age
  • BMI < 27
  • waist-to-hip ratio female<0.85; male < 0.98
Exclusion Criteria
  • metabolic diseases
  • Physical activity of competitive nature
  • Vegans and vegetarians
  • Intolerances and allergies to the foods under study

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
"kent'erbas" pecorino from extensive farming with crossover Arm 1kent'erbas cheese studyThis study was a 4-week, randomized, controlled, crossover clinical trial. Arm 1: Volunteers will be randomize to be allocated to eat 350g/week of "kent'erbas" pecorino from extensive farming with a crossover with arm 2 after 6 weeks of washout.
"industrial" pecorino from intensive farming with crossover Arm 2kent'erbas cheese studyThis study was a 4-week, randomized, controlled, crossover clinical trial. Arm 2 : Volunteers will be randomize to be allocated to eat 350g/week of "industrial" pecorino from intensive farming for 4 weeks in total, with a crossover with arm 1 after 6 weeks of washout.
Primary Outcome Measures
NameTimeMethod
Changes in plasma levels of DHA and acylethanolamides as Metabolic indices of PPAR-α induction increase in plasma levels of DHAAfter 4 weeks of treatment, 8 weeks of washout and 4 weeks of crossover

Changes in plasma levels of DHA)and modulation of the endocannabinoid system, through the biosynthesis of AEA, PEA, and OEA. All these parameters will be assessed as pmoles/ml of plasma

Secondary Outcome Measures
NameTimeMethod
Quotient respiratory changes measurement as metabolic flexibility indicesAfter 4 weeks of treatment, 8 weeks of washout and 4 weeks of crossover

Metabolic flexibility indices, through fasting differences in the respiratory quotient, measured as Liter/min of Oxygen consumption and carbon dioxide

Trial Locations

Locations (1)

University of Cagliari

🇮🇹

Monserrato, Cagliari, Italy

© Copyright 2025. All Rights Reserved by MedPath